Key Highlights

  • Cerenome (NASDAQ:CNSY) traded at USD 1.10 intraday on November 13, 2026, up 42.76%, on about 1.37 million shares, roughly twice its average volume, with a Market Value of about USD 8.24 million.
  • Interim results from the first ten patients in a multidose trial of REYOBIQ in leptomeningeal metastases were scheduled for presentation at a major neuro-oncology meeting on November 13, with a company symposium on November 14.
  • An earlier interim look at the first 15 patients in a Phase 2 glioblastoma trial showed median overall survival of 13 months against about 8 months historically for a standard comparator.
  • The company's diagnostics unit gained in-network coverage with a major national insurer from November 1, bringing contracted coverage to about 190 million lives.

Clinical Data Timing Drives the Move

The 42.76% jump in Cerenome on November 13, 2026 coincides with the presentation of new clinical data. The company, which traded as Plus Therapeutics until it changed its ticker to CNSY in August 2026, was scheduled to present interim results from the first ten patients in its multidose trial of REYOBIQ in leptomeningeal metastases at a major neuro-oncology meeting that day, and to host a symposium on November 14. It also set a conference call on clinical data for Monday, November 16. Leptomeningeal metastases occur when cancer spreads to the membranes around the brain and spinal cord, and treatment Options are very limited. No press release summarising the November 13 data was found at the time of writing, so the move appears to reflect anticipation of the presentation rather than a confirmed result. With a market value of only about USD 8.2 million, the stock can move sharply when interest in its data rises. The intraday Volume of about 1.37 million shares compares with a three-month average of about 653,000.

What REYOBIQ Is and Where Trials Stand

REYOBIQ, or rhenium Re186 obisbemeda, is a radiotherapeutic designed to deliver high doses of radiation directly into the brain or cerebrospinal fluid while limiting exposure to healthy tissue. Beyond the leptomeningeal programme, Cerenome is running the ReSPECT-GBM Phase 2 trial in recurrent glioblastoma, an aggressive brain tumour. The trial has enrolled 32 of 34 planned patients, with topline data expected in mid-2027. An interim look at the first 15 patients showed a median overall survival of 13 months, compared with about 8 months historically for patients treated with a standard antibody therapy. Early results from small, open-label groups can overstate benefit, so the full readout will matter more. Cerenome, based in Houston, also owns CNSide Diagnostics, which sells cerebrospinal fluid tests that count and profile tumour cells. In the third quarter it billed about USD 1.55 million on 222 tests, a figure that reflects gross billings rather than recognised revenue.

Funding and Volatility Risks

The diagnostics Business is gaining coverage. A major national insurer added the test to its network from November 1, joining regional plans in Florida and Michigan earlier in the autumn, for contracted coverage of about 190 million lives. The company also named a new chief business officer on November 10. Still, Cerenome (NASDAQ:CNSY) has a small market value and will likely need new Capital to complete its trials, which means dilution is a constant risk. The 52-week range of USD 0.43 to USD 19.00 shows how volatile the shares have been. Investors should look for the full data set from the meeting and the conference call before drawing conclusions.

Where Things Stand

Cerenome rose 42.76% to USD 1.10 on November 13, 2026 as interim REYOBIQ data were due at a major neuro-oncology meeting. The diagnostics unit is gaining payer coverage, but the company is small and will likely need funding. Watch the November 16 call, full trial data and any capital raise.